Company Name ProNAi Therapeutics
Mailing Address 46701 Commerce Center Drive Plymouth, MI 48170 USA
Company Description ProNAi Therapeutics, Inc. is an emerging biopharmaceutical company that is leveraging its novel and proprietary nucleic acid-based interfering technology, DNAi, to advance a next generation of therapies for patients with cancer and other complex genetic diseases.
Proceeds Purposes The Series D funding will be used to advance PNT2258 in several Phase II clinical studies in patients with relapsed or treatment refractory non-Hodgkin’s lymphoma including those with diffuse large B-cell lymphoma (DLBCL),Richter’s transformation, and follicular lymphoma (FL). Proceeds will also be used to support drug manufacturing, advance development of preclinical drug candidates, and build ProNAi’s organization in Michigan.